Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq ... collected cohort of samples from its ASCEND 2 study. The analysis indicated an overall sensitivity of 55% in cancers without ...

We have a Very High Uncertainty Rating on Exact Sciences. Key risks to our valuation include competitive risks related ... of our people and exacting analysis of our research processes.

Q4 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsMatt Shimao - Head of Investor RelationsNeil Barua ...

--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of ... in a prospectively collected cohort of samples from its ASCEND 2 study. The analysis indicated an overall sensitivity ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...